Elinogrel, an orally and intravenously available ADP-receptor antagonist

Area of Science:

• Cardiology
• Pharmacology

Background:

• Aspirin and clopidogrel are standard antiplatelet therapies post-coronary intervention or acute coronary syndrome.
• High interindividual variability in response to clopidogrel affects up to 44% of patients, impacting treatment efficacy.
• Platelet function testing (PFT) can identify high-risk patients, but PFT-guided therapy has not shown improved prognostic outcomes in recent trials.

Purpose of the Study:

• To review the investigational drug elinogrel as a personalized antiplatelet therapy.
• To highlight elinogrel's potential to overcome poor response to standard antiplatelet agents.

Main Methods:

• Review of existing literature on antiplatelet therapy and elinogrel.
• Comparison of elinogrel's pharmacological profile and clinical effects with clopidogrel.

Main Results:

• Elinogrel is a novel, reversible ADP-receptor antagonist available in oral and intravenous forms.
• Elinogrel demonstrates more rapid, less variable, and more complete platelet inhibition compared to clopidogrel.
• Elinogrel administration did not significantly increase bleeding complications.

Conclusions:

• Elinogrel presents a promising alternative for personalized antiplatelet therapy.
• The drug's efficacy and safety profile suggest advantages over clopidogrel in specific patient populations.
• Further investigation into elinogrel's role in preventing ischemic events is warranted.